Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)
Hengmiao Cheng(Pfizer (United States)), John C. Kath(Pfizer (United States)), Alexei Brooun(Pfizer (United States)), Ping Chen(Shandong Jiaotong University), Luke R. Zehnder(University of Minnesota), Ravi Visswanathan(Pfizer (United States)), Martha A. Ornelas(Pfizer (United States)), Caroline B. Ho(Pfizer (United States)), Neil B. Grodsky(Pfizer (United States)), Shubha Bagrodia(Scripps Research Institute), Robert S. Kania(RG Biopharma (United States)), Chau Almaden(Pfizer (United States)), Li Shao, Hong Shen(University of Michigan), Judith G. Deal(Pfizer (United States)), Susan E. Kephart(Pfizer (United States)), Fanxiu Meng(WuXi AppTec (China)), Rachel E. Kosa(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Sergei Timofeevski(Pfizer (United States)), Mehran Jalaie(Pfizer (United States)), Mary E. Spilker(Scripps Research Institute), Gary M. Gallego(Theravance Biopharma (United States)), Simon Bailey(The University of Melbourne), Feng Xu(Nanchang University), Hovhannes J. Gukasyan(Pfizer (United States)), Suvi T. M. Orr(Tracon Pharmaceuticals (United States)), Mason Pairish(Pfizer (United States)), Stephen E. Kaiser(Pfizer (United States)), Ling Liu(Henan University of Science and Technology), Ya‐Li Deng(Pfizer (United States)), Xiaolin Kang(Pfizer (United States)), Zhenxiong Wang(Pfizer (United States)), Scott C. Sutton(Pfizer (United States)), Shijian Ren(WuXi AppTec (China)), Jennifer Lafontaine(Pfizer (United States)), Simon Planken(Pfizer (United States)), Buwen Huang(Pfizer (United States)), Matthew D. Falk(Pfizer (United States))
Cited by 40
Related Papers
Correction: Corrigendum: The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes
|Scientific Reports|2016|2.1k
METLIN: A Technology Platform for Identifying Knowns and Unknowns
|Analytical Chemistry|2018|951
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650